文献速递精神分裂症与精神病性障碍

前额叶精神分裂症风险基因共表达与患者治疗反应相关

Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients.
PubMed 文献 · Biol Psychiatry · 2019-04-03

研究在前额叶皮质死后RNA测序数据中识别并复制了富集精神分裂症风险位点的共表达模块,构建多基因共表达指数(PCI),并在奥氮平治疗患者中验证PCI与阳性症状域治疗反应相关。

要点

  • 前额叶皮质存在富集精神分裂症风险基因的共表达模块,并在多个数据集中复制。
  • 基于预测共表达的遗传多态性构建的PCI与模块共表达相关,并在独立脑转录组数据中复制。
  • PCI与奥氮平治疗的精神分裂症患者阳性症状域短期治疗反应相关。

核心结论

  • 前额叶皮质中富集精神分裂症风险基因的共表达通路与精神分裂症患者治疗反应相关。
  • 该共表达通路可能受与其相关的转录因子和microRNA共同调控。

研究设计与样本

  • 在2个前额叶皮质死后RNA测序数据集(n=688)中识别基因共表达网络,并在另外4个数据集(n=1295)中复制。
  • 通过生物信息学分析筛选风险模块的潜在调控因子,并构建多基因共表达指数(PCI)。
  • 在2个独立脑转录组数据集(n=131)中复制PCI与共表达的关联。
  • 在2个独立奥氮平治疗精神分裂症患者样本(n=167)中检验PCI与短期治疗反应的关联。

主要发现

  • 识别并复制了一个富集精神分裂症风险位点的单一模块(10个位点中的13个风险基因,p值<.001)。
  • 生物信息学筛选发现2个转录因子和3个microRNA与风险模块相关。
  • PCI与模块共表达的关联在2个独立脑转录组数据集(n=131)中成功复制(p值<.05)。
  • PCI在两个临床队列中均与阳性症状域治疗反应相关(p值<.05)。

关键数值与推荐

  • 风险模块富集精神分裂症风险位点的复制显著性为p值<.001。
  • PCI与共表达关联复制的显著性为p值<.05。
  • PCI与治疗反应关联的显著性为p值<.05。

临床怎么用

  • PCI作为近似模块共表达的遗传指标,可能有助于提示精神分裂症患者对奥氮平阳性症状域治疗的反应。
  • 前额叶风险基因共表达通路及其调控因子可作为治疗反应相关机制研究的候选方向。

局限性

  • 原文未报告PCI对治疗反应预测效能的阈值或临床可用的分类标准。
  • 治疗反应分析仅涉及奥氮平治疗的短期反应,未报告其他药物或长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gene coexpression networks are relevant to functional and clinical translation of schizophrenia risk genes. We hypothesized that schizophrenia risk genes converge into coexpression pathways that may be associated with gene regulation mechanisms and with response to treatment in patients with schizophrenia. METHODS: We identified gene coexpression networks in two prefrontal cortex postmortem RNA sequencing datasets (n = 688) and replicated them in four more datasets (n = 1295). We identified and replicated (p values < .001) a single module enriched for schizophrenia risk loci (13 risk genes in 10 loci). In silico screening of potential regulators of the schizophrenia risk module via bioinformatic analyses identified two transcription factors and three microRNAs associated with the risk module. To translate postmortem information into clinical phenotypes, we identified polymorphisms predicting coexpression and combined them to obtain an index approximating module coexpression (Polygenic Coexpression Index [PCI]). RESULTS: The PCI-coexpression association was successfully replicated in two independent brain transcriptome datasets (n = 131; p values < .05). Finally, we tested the association between the PCI and short-term treatment response in two independent samples of patients with schizophrenia treated with olanzapine (n = 167). The PCI was associated with treatment response in the positive symptom domain in both clinical cohorts (p values < .05). CONCLUSIONS: In summary, our findings in 1983 samples of human postmortem prefrontal cortex show that coexpression of a set of genes enriched for schizophrenia risk genes is relevant to treatment response. This coexpression pathway may be coregulated by transcription factors and microRNA associated with it.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pergola G, Di Carlo P, Jaffe AE, et al. Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients. Biol Psychiatry. 2019. PMID: 31126695. doi:10.1016/j.biopsych.2019.03.981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。